Andreas Keller

• Defining and driving the commercial brand strategy of the franchise across the different local operating companies • Evaluate, review and prioritize LCM opportunities for the franchise • Reviewing, challenging and approving financial forecasting across EUCAN • Close collaboration with affiliates to optimise local implementation of aligned strategic imperatives and tactics

• Heading cross-functional Daxas (PDE4 inhibitor) launch team to develop global strategy and ensure launch readiness • Development of global campaign and messaging for 1st in class COPD treatment (PDE4 inhibitor) • Partnering strategy and management of global alliances • Development of sales forecasts and pricing options • Assessment of country launch readiness to ensure successful local implementation of aligned strategic imperatives and tactics

• Establishing a global OTC business unit to maximise the commercial value of the global and regional OTC portfolio • 1st centralised European wide Rx to OTC switch for blockbuster brand Pantoprazol closely collaborating with a cross-functional team • Market shaping activities and development of the global OTC campaign for the 1st PPI over the counter • Heading international brand team for the OTC Gastro portfolio

• Foundation of a local operating company in Greece • collaboration and negotiations with licensee executives and managers (Pfizer, Nycomed, Sanofi Aventis) to achieve annual financial goals and seize/complete new business opportunities • P&L responsibility for the business in the region

• Establishing and leading a medico marketing team for the respiratory franchise • Prelaunch and launch campaign and marketing concept for an innovative asthma product • Development of pricing strategy • Market shaping activities and premarketing campaign for a first in class COPD therapy • Member of the international core commercial respiratory team to establish brand strategy and value proposition